RE: Share price8 Apr 2026 12:11
Made transfer was a known pretty much factored in already. Clinical data, JV etc, is needed to drive the shareprice upwards. Something to prove it's working beyond its safety profile. Otherwise we just float about in a soup of Patient X treated and it was well tolerated.